AEON Biopharma (AEON) Competitors

$0.94 -0.01 (-1.05%)

Closing price 03:57 PM Eastern

Extended Trading

$0.94 +0.01 (+0.53%)

As of 06:59 PM Eastern

AEON vs. ANIX, COYA, AADI, NRXP, and ALDX

Should you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Anixa Biosciences (ANIX), Coya Therapeutics (COYA), Aadi Bioscience (AADI), NRx Pharmaceuticals (NRXP), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry.

How does AEON Biopharma compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

: 29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 0.9% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Anixa Biosciences had 3 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Anixa Biosciences and 0 mentions for AEON Biopharma. Anixa Biosciences' average media sentiment score of 0.34 beat AEON Biopharma's score of 0.00 indicating that Anixa Biosciences is being referred to more favorably in the media.
Company Overall Sentiment
Anixa Biosciences Neutral
AEON Biopharma Neutral
: Anixa Biosciences has higher revenue and earnings than AEON Biopharma. Anixa Biosciences is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anixa Biosciences $210K 479.00 -$10.93M -$0.33 N/A
AEON Biopharma N/A N/A -$36.63M -$2.43 N/A
: Anixa Biosciences presently has a consensus price target of $8.50, indicating a potential upside of 183.33%. Given Anixa Biosciences' higher probable upside, research analysts clearly believe Anixa Biosciences is more favorable than AEON Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anixa Biosciences
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
AEON Biopharma
0 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
3.00
: AEON Biopharma's return on equity of 0.00% beat Anixa Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Anixa Biosciences N/A -70.95% -62.53%
AEON Biopharma N/A N/A -994.63%
: Anixa Biosciences has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Company	Overall Sentiment
Anixa Biosciences	Neutral
AEON Biopharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	479.00	-$10.93M	-$0.33	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-70.95%	-62.53%
AEON Biopharma	N/A	N/A	-994.63%

Summary

Anixa Biosciences beats AEON Biopharma on 10 of the 15 factors compared between the two stocks.

How does AEON Biopharma compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

: 39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by insiders. Comparatively, 0.9% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Coya Therapeutics had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Coya Therapeutics and 0 mentions for AEON Biopharma. Coya Therapeutics' average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score.
Company Overall Sentiment
Coya Therapeutics Neutral
AEON Biopharma Neutral
: Coya Therapeutics has higher revenue and earnings than AEON Biopharma. Coya Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coya Therapeutics $7.95M 12.54 -$21.23M -$1.27 N/A
AEON Biopharma N/A N/A -$36.63M -$2.43 N/A
: Coya Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
: AEON Biopharma has a net margin of 0.00% compared to Coya Therapeutics' net margin of -267.13%. AEON Biopharma's return on equity of 0.00% beat Coya Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Coya Therapeutics -267.13% -62.76% -53.84%
AEON Biopharma N/A N/A -994.63%
: Coya Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 276.47%. Given Coya Therapeutics' higher probable upside, research analysts clearly believe Coya Therapeutics is more favorable than AEON Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coya Therapeutics
1 Sell rating(s)
0 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.67
AEON Biopharma
0 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
3.00

Company	Overall Sentiment
Coya Therapeutics	Neutral
AEON Biopharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	12.54	-$21.23M	-$1.27	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-267.13%	-62.76%	-53.84%
AEON Biopharma	N/A	N/A	-994.63%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Coya Therapeutics beats AEON Biopharma on 9 of the 15 factors compared between the two stocks.

How does AEON Biopharma compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

: 52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 37.3% of Aadi Bioscience shares are held by insiders. Comparatively, 0.9% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
: In the previous week, Aadi Bioscience had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for Aadi Bioscience and 0 mentions for AEON Biopharma. Aadi Bioscience's average media sentiment score of 0.00 equaled AEON Biopharma'saverage media sentiment score.
Company Overall Sentiment
Aadi Bioscience Neutral
AEON Biopharma Neutral
: AEON Biopharma has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aadi Bioscience $25.07M 3.93 -$65.76M -$2.35 N/A
AEON Biopharma N/A N/A -$36.63M -$2.43 N/A
: Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.
: AEON Biopharma has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. AEON Biopharma's return on equity of 0.00% beat Aadi Bioscience's return on equity.
Company Net Margins Return on Equity Return on Assets
Aadi Bioscience -246.06% -71.87% -57.28%
AEON Biopharma N/A N/A -994.63%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aadi Bioscience
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
AEON Biopharma
0 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
3.00

Company	Overall Sentiment
Aadi Bioscience	Neutral
AEON Biopharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.93	-$65.76M	-$2.35	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
AEON Biopharma	N/A	N/A	-994.63%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Aadi Bioscience and AEON Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does AEON Biopharma compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

: Company Net Margins Return on Equity Return on Assets
NRx Pharmaceuticals N/A N/A -265.03%
AEON Biopharma N/A N/A -994.63%
: NRx Pharmaceuticals currently has a consensus price target of $38.25, indicating a potential upside of 1,158.22%. Given NRx Pharmaceuticals' higher possible upside, analysts clearly believe NRx Pharmaceuticals is more favorable than AEON Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NRx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.50
AEON Biopharma
0 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
3.00
: NRx Pharmaceuticals has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.
: In the previous week, NRx Pharmaceuticals had 4 more articles in the media than AEON Biopharma. MarketBeat recorded 4 mentions for NRx Pharmaceuticals and 0 mentions for AEON Biopharma. NRx Pharmaceuticals' average media sentiment score of 1.54 beat AEON Biopharma's score of 0.00 indicating that NRx Pharmaceuticals is being referred to more favorably in the media.
Company Overall Sentiment
NRx Pharmaceuticals Very Positive
AEON Biopharma Neutral
: NRx Pharmaceuticals has higher revenue and earnings than AEON Biopharma. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NRx Pharmaceuticals $1.23M 82.06 -$28.62M -$1.39 N/A
AEON Biopharma N/A N/A -$36.63M -$2.43 N/A
: 4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-265.03%
AEON Biopharma	N/A	N/A	-994.63%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Company	Overall Sentiment
NRx Pharmaceuticals	Very Positive
AEON Biopharma	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	82.06	-$28.62M	-$1.39	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A

Summary

NRx Pharmaceuticals beats AEON Biopharma on 10 of the 14 factors compared between the two stocks.

How does AEON Biopharma compare to Aldeyra Therapeutics?

AEON Biopharma (NASDAQ:AEON) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

: AEON Biopharma's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
AEON Biopharma N/A N/A -994.63%
Aldeyra Therapeutics N/A -63.75% -41.27%
: Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 219.77%. Given Aldeyra Therapeutics' higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than AEON Biopharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AEON Biopharma
0 Sell rating(s)
1 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
3.00
Aldeyra Therapeutics
1 Sell rating(s)

2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: AEON Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.
: In the previous week, Aldeyra Therapeutics had 21 more articles in the media than AEON Biopharma. MarketBeat recorded 21 mentions for Aldeyra Therapeutics and 0 mentions for AEON Biopharma. Aldeyra Therapeutics' average media sentiment score of 0.04 beat AEON Biopharma's score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media.
Company Overall Sentiment
AEON Biopharma Neutral
Aldeyra Therapeutics Neutral
: Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AEON Biopharma N/A N/A -$36.63M -$2.43 N/A
Aldeyra Therapeutics N/A N/A -$33.85M -$0.57 N/A
: 22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 0.9% of AEON Biopharma shares are held by company insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Aldeyra Therapeutics	N/A	-63.75%	-41.27%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
AEON Biopharma	Neutral
Aldeyra Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.57	N/A

Summary

Aldeyra Therapeutics beats AEON Biopharma on 9 of the 13 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AEON vs. The Competition

Export

Metric	AEON Biopharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.04M	$886.55M	$6.25B	$11.77B
Dividend Yield	N/A	4.84%	2.74%	5.26%
P/E Ratio	5.22	1.71	29.25	27.07
Price / Sales	N/A	120.63	504.14	75.42
Price / Cash	N/A	20.07	43.30	53.90
Price / Book	-0.23	7.60	9.67	6.69
Net Income	-$36.63M	-$4.80M	$3.55B	$332.64M
7 Day Performance	-4.51%	-0.05%	1.70%	2.01%
1 Month Performance	5.76%	5.50%	5.62%	9.19%
1 Year Performance	76.23%	30.96%	34.42%	39.59%

AEON Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AEON AEON Biopharma	N/A	$0.94 -1.1%	N/A	N/A	$24.04M	N/A	5.22	5	Gap Down
ANIX Anixa Biosciences	2.4042 of 5 stars	$3.02 +1.7%	$8.50 +181.5%	N/A	$101.26M	$210K	N/A	5	Analyst Upgrade
COYA Coya Therapeutics	1.9362 of 5 stars	$4.26 -3.3%	$16.00 +276.0%	N/A	$99.81M	$7.95M	N/A	6	News Coverage Positive News Upcoming Earnings
AADI Aadi Bioscience	N/A	$4.03 -3.4%	N/A	N/A	$99.53M	$25.07M	N/A	40
NRXP NRx Pharmaceuticals	3.6439 of 5 stars	$2.95 -2.8%	$38.25 +1,198.8%	N/A	$97.39M	$1.23M	N/A	2	Positive News Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AEON Biopharma (AEON) Competitors

AEON vs. ANIX, COYA, AADI, NRXP, and ALDX

How does AEON Biopharma compare to Anixa Biosciences?

Summary

How does AEON Biopharma compare to Coya Therapeutics?

Summary

How does AEON Biopharma compare to Aadi Bioscience?

Summary

How does AEON Biopharma compare to NRx Pharmaceuticals?

Summary

How does AEON Biopharma compare to Aldeyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AEON Biopharma (AEON) Competitors

AEON vs. ANIX, COYA, AADI, NRXP, and ALDX

How does AEON Biopharma compare to Anixa Biosciences?

Summary

How does AEON Biopharma compare to Coya Therapeutics?

Summary

How does AEON Biopharma compare to Aadi Bioscience?

Summary

How does AEON Biopharma compare to NRx Pharmaceuticals?

Summary

How does AEON Biopharma compare to Aldeyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools